NeuroOne Medical Technologies Corporation (NMTC) Stock Price & Analysis
NeuroOne Medical Technologies Corporation (NMTC) closed at USD 1.04 on Thursday, October 15, 2026, down 1.89% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 1.06; the Oct 15, 2026 session ranged USD 1.01–1.08 on volume of 169,045 shares. Market capitalization is $9.47M, with a 52-week range of USD 0.96–6.12 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:11 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NMTC.md
Key facts (NMTC)
- Analysts: Buy (mean 1.67 on a 1–5 scale) (3 analysts), mean target USD 7.27 (range 5–8.8).
- Total return with dividends: 1Y -79.9% vs S&P 500 +18.1%; 5Y -94.2% vs S&P 500 +85.1%.
- Next earnings: 2026-08-13, EPS estimate USD -0.19, revenue estimate $3.8M.
Analysts (NMTC)
Consensus Buy (mean 1.67 on a 1–5 scale), 3 analysts; mean target USD 7.27 (low 5, high 8.8).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-14 | Maxim Group | Target lowered | Buy | $13 → $5 |
Total return (dividends reinvested) (NMTC)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | -79.9% | -94.2% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -80.0% | -43.4% |
| Volatility (annualized) | 80.3% | 108.0% |
| Max drawdown | -83.3% (Jan 2026→Oct 2026) | -94.2% (Oct 2021→Oct 2026) |
Key Statistics (as of October 16, 2026 at 05:11 UTC)
| Price | USD 1.04 |
|---|---|
| Change | ▼ 1.89% (down) |
| Previous Close | USD 1.06 |
| Open | USD 1.05 |
| Day Range | USD 1.01 – 1.08 |
| 52-Week Range | USD 0.96 – 6.12 |
| Volume | 169,045 shares |
| Market Cap | $9.47M |
| Exchange | NCM |
Technical Analysis (NMTC)
Nexqual's technical model rates NMTC "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:11 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 30 (neutral) |
| vs SMA50 | Below (USD 1.51) |
| MACD | -0.14 (negative) |
Analyst Ratings (NMTC)
Wall Street analysts rate NMTC "Buy" based on 3 analysts, with a mean price target of USD 7.27 (range USD 5–8.8), per Nexqual as of October 16, 2026 at 05:11 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 7.27 |
| High Target | USD 8.8 |
| Low Target | USD 5 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (NMTC)
| Next Earnings Date | 2026-08-13 |
|---|---|
| Revenue Estimate | $3.80M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.28 vs est -0.22 ▼ miss |
| 2025-12-31 | USD -0.18 vs est -0.24 ▲ beat |
| 2025-09-30 | USD -0.24 vs est -0.24 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Financials & Fundamentals (NMTC)
| Total Revenue | $12.47M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +16.30% |
| Gross Margin | +23.00% |
| Operating Margin | -122.87% |
| Profit Margin | -59.71% |
| ROE | -124.66% |
| Debt / Equity | 0.05 |
| Current Ratio | 2.84 |
| Total Cash | $2.05M |
| Total Debt | $175,345 |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Financial Health Score (NMTC)
Nexqual rates NeuroOne Medical Technologies Corporation's overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:11 UTC.
| Growth | Strong — Revenue +16% YoY (latest Q) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $2M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$7M (TTM) |
| Efficiency | Critical — ROE -125%, ROA -58.1% |
Ownership (NMTC)
| Insider Ownership | +25.44% |
|---|---|
| Institutional Ownership | +22.45% |
| Shares Outstanding | 9.11M |
| Float | 6.26M |
| Short % of Float | +2.03% |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Leadership (NMTC)
NeuroOne Medical Technologies Corporation is led by David A. Rosa (age 61), President, CEO & Director, per Nexqual as of October 16, 2026 at 05:11 UTC.
| President, CEO & Director | David A. Rosa (age 61) |
|---|---|
| Chief Financial Officer | Christopher R. Volker |
| Co-Founder, Business Development Director & Medical Sales Liaison | Mark Christianson (age 58) |
| Chief Technology Officer | Steven Mertens (age 62) |
| Vice President of Marketing | Hijaz Haris |
Major Backers & Investors (NMTC)
Notable institutional backers of NeuroOne Medical Technologies Corporation include Bleichroeder LP, Bard Associates Inc., Perkins Capital Management, Inc., according to Nexqual as of October 16, 2026 at 05:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Bleichroeder LP | 7.32% |
| Bard Associates Inc. | 3.35% |
| Perkins Capital Management, Inc. | 2.69% |
| Sio Capital Management, LLC | 0.91% |
| Fidelity | 0.82% |
| Renaissance Technologies | 0.78% |
| Essex Investment Management Co LLC | 0.48% |
| Cambridge Investment Research Advisors Inc. | 0.31% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.28% |
| Geode Capital | 1.03% |
Source: Nexqual, October 16, 2026 at 05:11 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ESTA | Establishment Labs Holdings Inc | USD 61.36 | ▲ 4.98% |
| ALMR | Alamar Biosciences, Inc. | USD 27.42 | ▲ 16.58% |
| INSP | Inspire Medical Systems, Inc. | USD 70.12 | ▲ 1.83% |
| BFLY | Butterfly Network, Inc. | USD 7.85 | ▼ 3.09% |
| AXGN | AxoGen, Inc. | USD 35.63 | ▼ 1.49% |
| UFPT | UFP Technologies, Inc. | USD 297.19 | ▲ 0.99% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:11 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt